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The ﬁeld of mechanical circulatory support (MCS) has
made signiﬁcant progress that has been achieved over a
long period of time and required tremendous efforts from
various groups around the globe: from the early 1960s,
when Moulopoulos and Kolff pioneered intra-aortic bal-
loon counterpulsation (1) and Andrian Kantrowitz strug-
gled to apply it clinically, to the early 1980s, when again
Kolff’s group pioneered the ﬁrst total artiﬁcial heart at the
University of Utah (2). Since then, further intensive exper-
imental and clinical research has led to the relatively
recent establishment of long-term MCS as a bridge to heart
transplantation. The ﬁeld is now attempting to further expand
MCS as lifetime therapy (so-called “destination therapy”
[DT]) in patients with advanced chronic heart failure (HF).See page 1751HF is a growing epidemic around the globe, and it often
progresses to its advanced stages despite current optimal
medical therapies. Patients with advanced HF are consid-
ered for heart transplantation, MCS, intravenous inotropic
support, or hospice. MCS has already proven effective as a
bridge to heart transplantation. Furthermore, landmark
randomized controlled trials have led to Food and Drug
Administration (FDA) approval of the ﬁrst pulsatile, and
then later, continuous-ﬂow MCS devices as lifetime DT
therapy for carefully selected transplant-ineligible patients.
The question arising now, a few years after the approval
by the FDA of the continuous-ﬂow HeartMate II device
(Thoratec, Pleasanton, California) for DT, is whether the
application of this therapy has been working as well in the
real world as in the initial pivotal clinical trial (3), and*Editorials published in the Journal of the American College of Cardiology reﬂect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the Division of Cardiovascular Medicine & Cardiac Mechanical Support
Program, University of Utah and the Utah Transplantation Afﬁliated Hospitals
(UTAH) Cardiac Transplant Program, Salt Lake City, Utah. Dr. Drakos has received
funding from the Doris Duke Foundation (Clinical Scientist Development Grant
7/2013) and the Deseret Foundation/IRMF (#00571); and is a consultant for
Abiomed.consequently, whether this therapy could now be appropri-
ately expanded further in the United States and the rest of
the world, where resources might be even more limited.
In this issue of the Journal, Jorde et al. (4) used the na-
tional INTERMACS (Interagency Registry for Mechani-
cally Assisted Circulatory Support) to prospectively examine
outcomes of the ﬁrst 247 U.S. patients who received the
HM II left ventricular assist device as lifetime therapy (DT)
after the FDA approval. The investigators compared their
ﬁndings to the outcomes achieved in the multicenter clinical
trial cohort (n ¼ 133) to see whether the clinical trial out-
comes (3) were successfully translated into every day clinical
practice. This study was one of the requirements that the
FDA set when it approved the HM II left ventricular assist
device for DT. Patients were enrolled from January to
September 2010 at 61 U.S. centers and were followed for
2 years. Kaplan-Meier survival at 12 and 24 months for the
post-approval group was 74  3% and 61  3%, respec-
tively, compared with the trial’s group of 68  4% and
58  4% (p ¼ NS). These survival outcomes were accom-
panied by early and sustained improvements in quality of
life and functional status that were similar to the previously
published improvements derived from the pre-approval trial
data. Adverse events such as infections, strokes, bleeding,
and pump replacements were either reduced or trended
toward a decrease, although the adverse event burden re-
mained highly signiﬁcant. Speciﬁcally, at the 2-year follow-
up, only 43% of the patients were alive and free of a serious
adverse event (e.g., stroke, infection, or pump replacement).
If we also add the bleeding complications (both perioperative
and long-term), we can understand the current unattractive
adverse event proﬁle of this therapy in DT patients. In this
context, it is particularly notable that the study was limited
by the fact that the adverse events and complications data
for the post-approval cohort might be underestimated, given
that they were collected by treating physicians through
INTERMACS and not adjudicated by a clinical events
committee, as was the case in the multicenter clinical trial.
Along the same lines, the investigators acknowledged the
discrepancies between the reported increased hemolysis
(from 3.8% in the clinical trial to 6.5% in the post-approval
cohort), and that this was not accompanied by increased
reporting of pump thrombosis as would be expected (the
pump thrombosis rate remained the same at approximately
3.7%). This might also reﬂect variability between centers in
clinical diagnosis and management of hemolysis and pump
thrombosis. Given the recent reports that indicated in-
creased prevalence of pump thrombosis that began approx-
imately in 2010 to 2011 (i.e., close to the time patients
were enrolled in this study), this issue warrants further
investigation.
Overall, the results reported in this issue of the Journal
are consistent with the outcomes summarized in the latest
ﬁfth annual INTERMACS report (5). Taking into con-
sideration that the mean survival of advanced HF patients
who receive intravenous inotropic support is only 6 months,
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ﬂow left ventricular assist devices has dramatically increased
the life expectancy of these patients over the last few years.
This is clearly shown in Figure 8 included by Jorde et al. (4)
in the discussion section of their study, which com-
pared survival outcomes from trials and registry reports
among ﬁrst generation pulsatile devices, second generation
continuous-ﬂow devices, and optimal medical therapy per-
formed over the last 15 years. However, as physicians, we
should always remind ourselves that the life-saving nature
of a therapy is not the only criterion that a patient considers
when making this kind of decision. The majority of patients
consider expected quality of life and functional capacity to be
equally important as expected survival (6). In this context, 3
of the main issues that are currently being debated within the
advanced HF ﬁeld include the following. 1) In patients who
are eligible for heart transplantation, is long-term MCS
therapy ready for a head-to-head trial as an alternative to
transplantation? 2) In patients with refractory HF who
are ineligible for heart transplantation due to age and/or
comorbidities, is MCS a safe and viable ﬁrst-line, standard-
of-care therapy (7)? 3) Do patients with moderately advanced
HF, who are not yet ill enough to be candidates for heart
transplantation, do better with long-term MCS therapy or
standard medical therapy (8)? How do the results of the study
reported in this issue of the Journal affect these 3 issues and
how are they further integrated into clinical practice?
In regard to the ﬁrst issue of a head-to-head comparison
between long-term MCS and heart transplantation, the data
reported by Jorde et al. (4), in combination with other
available evidence, would probably support that there is notFigure 1
Survival Rates in Trials and Registry Reports of Heart Tran
Lifetime Therapy (DT)
‘Heart Transplant ISHLT 2010–12’ – survival of adult patients transplanted in 2010–201
Transplantation (ISHLT), data provided by Josef Stehlik, Leah B. Edwards, Anna Y. Kuchery
from Figure 8 in Jorde et al. (4). DT ¼ destination therapy; HM ¼ HeartMate; LVAD ¼ lefyet sufﬁcient equipoise to perform such a trial. Although
survival outcomes with long-term MCS have steadily
improved over the last 15 years, these outcomes are still
clearly inferior to the 1- and 2-year survival results derived
from heart transplantation (Fig. 1). Longer term survival
results derived from large patient populations on MCS
are still pending. Some may object that the comparison
depicted in Figure 1 is not completely fair, given that the
patients receiving heart transplantation are usually at lower
risk compared with the patients enrolled in the DT trials
and DT registry reports. However, as shown in the latest
INTERMACS report, the survival rates with MCS in these
2 study groups (listed for and bridged to transplant vs. DT)
are not so different. Speciﬁcally, the unadjusted 1-year sur-
vival difference between MCS patients listed for and bridged
to transplantation versus DT was relatively small, and after
adjusting for risk factor prevalence, the difference in pre-
dicted 1-year survival was approximately 5% (5). These
long-term MCS survival results, along with the MCS-
related adverse event burden (which seems far more
severe than the one associated with transplantation),
suggest that long-term MCS using currently available
devices is not ready for a direct bras de fer with heart
transplantation.
The second issue of using lifetime MCS as a ﬁrst-line,
standard-of-care therapy in patients with refractory HF
who are too ill and/or too old to be considered for heart
transplantation is an issue that sparks intense debate (7).
One of the main arguments criticizing such a strategy is
that there is a signiﬁcant overlap between risk factors for
poor outcome after heart transplantation and MCS as DT.splantation and Chronic Mechanical Circulatory Support as
2. Source: Transplant Registry of the International Society for Heart and Lung
avaya (personal communication, January 2014). All remaining survival curves derived
t ventricular assist device.
Table 1 Future Targets Critical for Progress of Long-Term MCS
Technological advances: smaller device size, wireless energy transfer
(infections, strokes, and/or quality of life), ﬂow autoregulation
Patient selection: multidisciplinary team approach, beneﬁt-to-risk ratio research
Patient management and/or understanding of biological consequences of
MCS: end organs, hematological system, immune system, skeletal muscles,
myocardium/bridge-to-recovery research
Cost reduction: device cost, complications, patient support system, cost-beneﬁt
research
MCS ¼ mechanical circulatory support.
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morbidity and mortality after heart transplantation, preclude
us from offering this therapy to our patients because of the
high likelihood for a poor outcome, loss of the donor organ
(which is a scarce resource), and at the same time, a large
expenditure of money (7). For the same reasons, some argue,
most of these patients should also not be offered MCS as
DT because of a high likelihood of poor outcome and even
larger money expenditure, which is also an increasingly
scarce resource (7). In addition, important long-term MCS
survival data are missing, and patient selection criteria are
not well deﬁned (7). In this context, the results of the study
published in this issue of the Journal do provide further
evidence derived from the post-FDA approval actual
patient-care setting that further strengthens the pre-approval
clinical trial data. In many transplant-ineligible patients,
despite the serious adverse event burden, the mortality and
quality of life with MCS as DT has signiﬁcantly improved.
This study did not provide much information on how to
better select and manage these patients to optimize long-
term outcomes and minimize serious adverse events, but
the ﬁeld is making slow and steady progress in these areas as
well. Putting everything together, it seems that we currently
have evidence supporting the notion that, for carefully
selected transplant-ineligible patients, lifetime MCS is a
reasonable therapeutic approach. However, these decisions
are usually not straight forward and should be made with
prudence by experienced clinicians within the context of
multidisciplinary committees in specialized HF centers.
Regarding the third issue of optimal therapeutic strategies
for moderately advanced, less ill HF patients, Jorde et al. (4)
stratiﬁed survival outcomes by severity of HF, as reﬂected
by the INTERMACS proﬁle levels. Speciﬁcally, in the
post-approval cohort, the survival at 1 and 2 years was 82%
and 69% for proﬁles 4 to 7 (healthier) versus 72% and 60%
for proﬁles 1 to 3 (sicker patients). The survival beneﬁt
observed in the healthier subgroup is encouraging for the
ongoing National Institutes of Health sponsored trial
REVIVE-IT (Randomized Evaluation of VAD Interven-
tion Before Inotropic Therapy). This trial is testing the
hypothesis that long-term MCS may improve both survival
and quality of life in patients with moderately advanced HF
who are neither inotrope-dependent nor exercise-intolerant,
and have not yet developed serious consequences (e.g.,
malnourishment, end-organ damage, and immobility) (8).
However, the adverse events results are not as promising.
The serious adverse events following MCS in the study by
Jorde et al. (4) were not stratiﬁed by severity of disease.
However, this kind of analysis was done in the latest
INTERMACS report, in which the rate of serious adverse
events following MCS was not improved in either the less
sick or younger HF patients (5).
Half a century after the ﬁrst description of what proved to
be the ﬁrst widely applied form of MCS (1), the ﬁeld is
slowly making its way forward. The medical and scientiﬁc
community within academia, medical centers, industry, andall of us who genuinely care for the ﬁeld to make progress
and fulﬁll its noble missions should concentrate on the major
targets mentioned in Table 1 to address many of the pre-
viously described issues in the near future. HF is a global
epidemic. The need is huge and immediate, and the work
that remains to be done is enormous (Table 1). Given the
more than 50-year-long struggles that the ﬁeld has gone
through and the magnitude of the clinical problem, a sense
of urgency is justiﬁed. Long-term MCS, ‘destination’ ther-
apy, and in general, ‘cardiac replacement’, as an invigorating
concept that inspired early workers in the ﬁeld indeed
proved to be during the last half century an Odyssey. The
journey will probably continue to be long, and, as in every
Odyssey, we need to remember that our real ‘destination’ is
nothing more than what we learn during the journey.
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